Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association’s Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America.
Shared 2 months ago
85 views
Shared 4 months ago
99 views
Shared 8 months ago
70 views
Shared 8 months ago
56 views
Shared 8 months ago
39 views
Shared 11 months ago
168 views
Shared 1 year ago
128 views
Shared 1 year ago
586 views
Shared 1 year ago
205 views
Shared 2 years ago
170 views
Shared 4 years ago
1K views
Shared 5 years ago
3.7K views
Shared 5 years ago
38K views
Shared 5 years ago
3K views
Shared 8 years ago
21K views
Shared 9 years ago
1.9K views
Shared 10 years ago
8.5K views
Shared 11 years ago
858 views
Shared 11 years ago
243 views
